# Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

Study · id `cardio:ct-nct04340908` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04340908](<https://clinicaltrials.gov/study/NCT04340908>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04340908

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

## Technical summary

Registry record NCT04340908. Randomized; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2022-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT04340908, source copy `cardio:ctgov-nct04340908-2021-10-07`, retrieved 2026-10-26)
- Started: 2021-01-01 (actual) (ClinicalTrials.gov record NCT04340908, source copy `cardio:ctgov-nct04340908-2021-10-07`, retrieved 2026-10-26)
- Primary completion: 2022-06-01 (anticipated) (ClinicalTrials.gov record NCT04340908, source copy `cardio:ctgov-nct04340908-2021-10-07`, retrieved 2026-10-26)
- Completion: 2023-06-01 (anticipated) (ClinicalTrials.gov record NCT04340908, source copy `cardio:ctgov-nct04340908-2021-10-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04340908, source copy `cardio:ctgov-nct04340908-2021-10-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04340908-2021-10-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery
- Condition: Diabetes Mellitus, Type 2
- Condition: Cardiac Surgery
- Intervention (Drug): Dapagliflozin 10 MG
- Intervention (Drug): Placebos
- Lead sponsor: Hongchang Guo
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)

## Provenance

Content hash: 3353fcc1548755ebbe1b9c95832b3e34abb8e7d9390510b8439e112851866a12
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
